» Articles » PMID: 23055686

Rituximab for Refractory Granulomatous Eye Disease

Overview
Journal Clin Ophthalmol
Publisher Dove Medical Press
Specialty Ophthalmology
Date 2012 Oct 12
PMID 23055686
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine the effectiveness of rituximab therapy for patients with granulomatous disease of the eye.

Methods: Retrospective review was undertaken of cases seen at a single institution for ocular antineutrophil cytoplasmic antibody-associated vasculitis or sarcoidosis with persistent ocular disease despite systemic therapy. All patients were treated with rituximab and followed for at least 6 months.

Results: Nine patients were identified (five with antineutrophil cytoplasmic antibody-associated vasculitis, four with sarcoidosis), and all were treated for at least 6 months. Eight experienced improvement of eye disease and were able to reduce prednisone and other drug therapies. One patient remained stable, but still required high dosages of prednisone. All five patients with lung disease improved with rituximab therapy. Rituximab treatment was well tolerated. Two patients discontinued the drug due to leukopenia; however, both patients reinstituted rituximab at modified doses.

Conclusion: Rituximab therapy was effective in controlling granulomatous ocular disease in most cases. The drug was corticosteroid-sparing and effective in refractory cases, with no severe adverse events encountered.

Citing Articles

D. Geraint James Lecture: The sarcoidosis saga: what insights from the past will guide us in the future.

Baughman R, Lower E Sarcoidosis Vasc Diffuse Lung Dis. 2023; 40(4):e2023057.

PMID: 38126494 PMC: 10964999. DOI: 10.36141/svdld.v40i4.15282.


Refractory multisystemic sarcoidosis, a diagnosis and treatment challenge: a case report.

Rodas Flores J, de Ceballos E, Hernandez-Cruz B, Munoz A, Machuca-Aguado J, Gallardo S J Med Case Rep. 2023; 17(1):303.

PMID: 37386509 PMC: 10311802. DOI: 10.1186/s13256-023-03996-w.


The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review.

Habibi M, Alesaeidi S, Zahedi M, Hakimi Rahmani S, Piri S, Tavakolpour S Biology (Basel). 2022; 11(12).

PMID: 36552276 PMC: 9774915. DOI: 10.3390/biology11121767.


Rituximab for non-infectious Uveitis and Scleritis.

Ng C, Sy A, Cunningham Jr E J Ophthalmic Inflamm Infect. 2021; 11(1):23.

PMID: 34396463 PMC: 8364894. DOI: 10.1186/s12348-021-00252-4.


How to Tackle the Diagnosis and Treatment in the Diverse Scenarios of Extrapulmonary Sarcoidosis.

Valeyre D, Jeny F, Rotenberg C, Bouvry D, Uzunhan Y, Seve P Adv Ther. 2021; 38(9):4605-4627.

PMID: 34296400 PMC: 8408061. DOI: 10.1007/s12325-021-01832-5.


References
1.
Lower E, Smith J, Martelo O, Baughman R . The anemia of sarcoidosis. Sarcoidosis. 1988; 5(1):51-5. View

2.
Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H . Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2007; 67(2):189-94. DOI: 10.1136/ard.2007.072967. View

3.
Lower E, Blau R, Gazder P, Tummala R . The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med. 1999; 8(7):949-54. DOI: 10.1089/jwh.1.1999.8.949. View

4.
Treon S, Ioakimidis L, Soumerai J, Patterson C, Sheehy P, Nelson M . Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009; 27(23):3830-5. PMC: 2727288. DOI: 10.1200/JCO.2008.20.4677. View

5.
Bomprezzi R, Pati S, Chansakul C, Vollmer T . A case of neurosarcoidosis successfully treated with rituximab. Neurology. 2010; 75(6):568-70. DOI: 10.1212/WNL.0b013e3181ec7ff9. View